Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Benzinga · 1d ago
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.